European life science competitiveness: Why IP is fundamental
On the occurrence of the EU presidency, we place the spotlight on suggested EU-legislations affecting IP-rights in the life science industry. With examples from the Swedish life science arena, we show the importance of IP-protection in the journey from academic research to products and therapies for patients.
IVA konferenscenter, Grev Turegatan 16 Stockholm
Seminariet sänds även digitalt.
In a quickly transforming world, the game is changing for the life science industry. An industry coming out of the pandemics with strong confidence of its importance, but where protectionism, nationalism, war and financial turmoil interfere with global just-in-time supply chains. At the same time, regulations and legislations change with the best intent for the benefit of patients. But how do these changes affect the industry’s possibilities for innovation and development of the therapies of the future?
Welcome to a seminar that highlights the importance of IP-protection throughout the life science innovation process where academic research is transformed into products and companies to fight diseases and sustain healthy life.
Moderator: Lotta Ljungqvist, chair of IVAs division of Biotechnology and chair of SwedenBIO.
Introduction by Elisabeth Björk, AstraZeneca
BLOCK 1: The start of the innovation journey
- Kristian Tryggvason, CEO, Alder Therapeutics
- Anders Persson, Executive Director Ecosystem Strategy & Innovation, AstraZeneca
- Jesper Hedberg, CEO, Testa center
- Johannes Hulthe, CEO and co-founder, Antaros
- Marika Nestor, CEO and founder Akiram
BLOCK 2: Company growth and investments necessary for bringing pharmaceuticals to the market
- Renée Aguiar-Lucander, CEO, Calliditas
- Gunilla Osswald, CEO, Bioarctic and member of IVAs division of Biotechnology
- Thomas Eldered, Executive Chairman Fleire Invest
Concluding panel: Which considerations are crucial for an EU legislation to support innovation?
The seminar will be held in English.